Toshio Iwasaki
Direktor/Vorstandsmitglied bei Cellfree Sciences Co., Ltd.
Profil
Toshio Iwasaki is currently an Outside Director at Cellfree Sciences Co., Ltd.
and a Director at ReqMed Co., Ltd.
He previously held positions as a Director at R-Tech Ueno, Ltd., an Outside Director at Quark Pharmaceuticals, Inc., and an Outside Director at IC-VEC Ltd.
He also served as a Senior Managing Director at Mitsubishi UFJ Capital Co., Ltd.
from 1999 to 2002.
Additionally, he was a Director at Anicom Holdings, Inc. from 2007 to 2012 and an Outside Director at Archetype Group Corp.
from 2010 to 2014.
He has also worked as an Auditor at eConservo, Inc. Mr. Iwasaki obtained his undergraduate degree from the University of Tokyo in 1970.
Aktive Positionen von Toshio Iwasaki
Unternehmen | Position | Beginn |
---|---|---|
Cellfree Sciences Co., Ltd.
Cellfree Sciences Co., Ltd. Medical/Nursing ServicesHealth Services Cellfree Sciences Co., Ltd. develops cell-free protein composition technology. The private company is based in Yokohama-shi, Japan. | Direktor/Vorstandsmitglied | 02.03.2011 |
ReqMed Co., Ltd.
ReqMed Co., Ltd. Pharmaceuticals: MajorHealth Technology ReqMed Co., Ltd. engages in drug development and consulting services. Its projects include development of pentosan polysulfate which alleviate pain symptoms of osteoarthritis, and eltoprazine which are used in the diseases such as attention-deficit hyperactivity disorder, cognitive impairment associated with schizophrenia and dyskinesia associated with Parkinson disease. The firm's clients include pharmaceutical and bio-pharmaceutical companies. The company was founded by Tadashi Matsumoto on May 12, 1998 and is headquartered in Machida, Japan. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Toshio Iwasaki
Unternehmen | Position | Ende |
---|---|---|
Mitsubishi UFJ Capital Co., Ltd.
Mitsubishi UFJ Capital Co., Ltd. Investment ManagersFinance Mitsubishi UFJ Capital Co., Ltd. (MUCAP) is a venture capital subsidiary of Mitsubishi UFJ Financial Group, Inc. (TSE: 8306; NYSE: MTU), founded in 1974. The firm is headquartered in Tokyo with additional offices in Nagoya and Osaka. | Direktor/Vorstandsmitglied | 01.12.2002 |
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Direktor/Vorstandsmitglied | - |
IC-VEC Ltd.
IC-VEC Ltd. Miscellaneous Commercial ServicesCommercial Services IC-VEC Ltd. is a biotechnology firm and do research and development for non-viral drug delivery systems. The company's therapeutic areas are cancer and liver diseases. IC-VEC plans to use its technology to develop DNA based and cancer vaccines. The company was founded in December 2001 by Andrew Miller and is headquartered in London, UK | Direktor/Vorstandsmitglied | - |
Archetype Group Corp.
Archetype Group Corp. Miscellaneous Commercial ServicesCommercial Services Archetype Corp. provides business incubation and consulting services. It offers hands-on incubation services for seed-to-early startups. Its business activities include web sector consulting as well as startup business investment and training. The company was founded by Jun Nakajima and Osamu Higuchi on May 1, 2006 and is headquartered in Tokyo, Japan. | Direktor/Vorstandsmitglied | - |
eConservo, Inc. | Comptroller/Controller/Auditor | - |
Ausbildung von Toshio Iwasaki
University of Tokyo | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
ANICOM HOLDINGS, INC. | Finance |
Private Unternehmen | 8 |
---|---|
R-Tech Ueno, Ltd.
R-Tech Ueno, Ltd. Pharmaceuticals: MajorHealth Technology R-Tech Ueno Ltd. engages in the research and development, manufacture and sale of pharmaceutical products. It operates through the following business divisions: New Pharmaceutical Research and Development, Pharmaceutical Manufacture and Sale, and Pharmaceutical Development Support and Contract Manufacturing Services. The New Pharmaceutical Research and Development business provides development for unmet medical needs area, orphan drug area, and anti-aging area. The Pharmaceutical Manufacture and Sale business handles the manufacture and sale of Rescula Eye Drops for glaucoma and ocular hypertension. The Pharmaceutical Development Support and Contract Manufacturing Services business covers the manufacture and sale of AMITIZA capsules for chronic idiopathic constipation. It also accepts contract manufacturing of eye drops, liquid drugs and liquid-filled hard capsules. The company was founded by Ryuji Ueno and Sachiko Kuno in September 1989 and is headquartered in Tokyo, Japan. | Health Technology |
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Health Technology |
Cellfree Sciences Co., Ltd.
Cellfree Sciences Co., Ltd. Medical/Nursing ServicesHealth Services Cellfree Sciences Co., Ltd. develops cell-free protein composition technology. The private company is based in Yokohama-shi, Japan. | Health Services |
IC-VEC Ltd.
IC-VEC Ltd. Miscellaneous Commercial ServicesCommercial Services IC-VEC Ltd. is a biotechnology firm and do research and development for non-viral drug delivery systems. The company's therapeutic areas are cancer and liver diseases. IC-VEC plans to use its technology to develop DNA based and cancer vaccines. The company was founded in December 2001 by Andrew Miller and is headquartered in London, UK | Commercial Services |
Mitsubishi UFJ Capital Co., Ltd.
Mitsubishi UFJ Capital Co., Ltd. Investment ManagersFinance Mitsubishi UFJ Capital Co., Ltd. (MUCAP) is a venture capital subsidiary of Mitsubishi UFJ Financial Group, Inc. (TSE: 8306; NYSE: MTU), founded in 1974. The firm is headquartered in Tokyo with additional offices in Nagoya and Osaka. | Finance |
ReqMed Co., Ltd.
ReqMed Co., Ltd. Pharmaceuticals: MajorHealth Technology ReqMed Co., Ltd. engages in drug development and consulting services. Its projects include development of pentosan polysulfate which alleviate pain symptoms of osteoarthritis, and eltoprazine which are used in the diseases such as attention-deficit hyperactivity disorder, cognitive impairment associated with schizophrenia and dyskinesia associated with Parkinson disease. The firm's clients include pharmaceutical and bio-pharmaceutical companies. The company was founded by Tadashi Matsumoto on May 12, 1998 and is headquartered in Machida, Japan. | Health Technology |
Archetype Group Corp.
Archetype Group Corp. Miscellaneous Commercial ServicesCommercial Services Archetype Corp. provides business incubation and consulting services. It offers hands-on incubation services for seed-to-early startups. Its business activities include web sector consulting as well as startup business investment and training. The company was founded by Jun Nakajima and Osamu Higuchi on May 1, 2006 and is headquartered in Tokyo, Japan. | Commercial Services |
eConservo, Inc. |